(Q44264227)

English

A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 December 2017

A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma (English)

1 reference

Europe PubMed Central

1 December 2017

0 references

ocular hypertension

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Scott M Whitcup

6

object named as

Scott M Whitcup

1 reference

Europe PubMed Central

1 December 2017

author name string

Robert S Noecker

1

1 reference

Europe PubMed Central

1 December 2017

Monte S Dirks

2

1 reference

Europe PubMed Central

1 December 2017

Neil T Choplin

3

1 reference

Europe PubMed Central

1 December 2017

Paula Bernstein

4

1 reference

Europe PubMed Central

1 December 2017

Amy L Batoosingh

5

1 reference

Europe PubMed Central

1 December 2017

Bimatoprost/Latanoprost Study Group

7

1 reference

Europe PubMed Central

1 December 2017

language of work or name

0 references

publication date

1 January 2003

1 reference

Europe PubMed Central

1 December 2017

American Journal of Ophthalmology

1 reference

Europe PubMed Central

1 December 2017

135

1 reference

Europe PubMed Central

1 December 2017

1

1 reference

Europe PubMed Central

1 December 2017

55-63

1 reference

Europe PubMed Central

1 December 2017

The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901827-5

7 January 2021

The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901827-5

7 January 2021

Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901827-5

7 January 2021

Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901827-5

7 January 2021

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901827-5

7 January 2021

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901827-5

7 January 2021

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901827-5

7 January 2021

Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901827-5

7 January 2021

Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901827-5

7 January 2021

A useful testing strategy in phase III trials: combined test of superiority and test of equivalence

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901827-5

7 January 2021

Target pressure--glaucomatologists' holey grail.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901827-5

7 January 2021

A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901827-5

7 January 2021

Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901827-5

7 January 2021

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9394%2802%2901827-5

7 January 2021

Identifiers

10.1016/S0002-9394(02)01827-5

1 reference

Europe PubMed Central

1 December 2017

release_vsr5harixzfznk46lzqdezeoqa

1 reference

https://api.fatcat.wiki/v0/release/vsr5harixzfznk46lzqdezeoqa

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44264227&oldid=2108989336"